Acrinova (ACRI) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
5 Jun, 2025Executive summary
Achieved strong financial performance in 2024, with significant growth in earnings and operational efficiency compared to 2023.
Major transactions included the sale of Euron 1 in Trelleborg and acquisition of two industrial properties in Helsingborg.
Continued focus on sustainable property development and energy efficiency, including installation of the largest solar plant to date.
Board proposes a dividend of SEK 0.40 per share for 2024.
Financial highlights
Rental income for 2024 was SEK 157.7m (143.3m), up 10% year-over-year.
Operating surplus increased to SEK 110.7m (92.6m), a 19.5% improvement.
Management result rose to SEK 49.9m (38.9m), up 28.3% year-over-year.
Net profit after tax was SEK 35.9m (7.8m), with EPS of SEK 0.52 (0.11).
Cash flow from operations was SEK 61.1m (71.2m); total cash flow for the year was SEK 38.1m (14.7m).
Outlook and guidance
Management sees a more stable interest rate environment supporting an active transaction market in 2025.
Ongoing and planned projects, including new logistics and industrial facilities, are expected to drive further growth.
Dividend of SEK 0.40 per share proposed for 2024, reflecting confidence in future cash flows.
Latest events from Acrinova
- Strategic refocus and major divestments led to higher net income and strong liquidity for 2025.ACRI
Q4 202527 Feb 2026 - Largest-ever property sale boosts profit and liquidity, enabling a strategic shift to development.ACRI
Q3 202525 Nov 2025 - Largest property divestment to date drives strategic refocus and solid H1 2025 results.ACRI
Q2 202513 Aug 2025 - Stark resultattillväxt, hög uthyrningsgrad och nya projekt driver Acrinovas positiva utveckling.ACRI
Q3 202413 Jun 2025 - Revenue and management result up, strong occupancy, stable outlook, and new acquisitions.ACRI
Q2 202413 Jun 2025 - Earnings surged and a transformative property divestment was initiated, reshaping Acrinova's strategy.ACRI
Q1 20256 Jun 2025